Contact: Investors: Traci McCarty BioMarin Pharmaceutical Inc[removed]

First Page		Document Content
Date: 2014-06-08 18:46:42 Genetic genealogy BioMarin Pharmaceutical Glycogen storage disease type II Acid alpha-glucosidase Lysosomal storage disease Mucopolysaccharidosis Alglucosidase alfa Neuronal ceroid lipofuscinosis Tetrahydrobiopterin Health Rare diseases Medicine		Contact: Investors: Traci McCarty BioMarin Pharmaceutical Inc[removed] Add to Reading List Source URL: amdapompe.ehclients.com Download Document from Source Website File Size: 91,47 KB Share Document on Facebook

	Implantação de um protocolo laboratorial para o diagnóstico de Mucopolissacaridoses VI e VII* Evaluation of a laboratorial protocol for Mucopolysaccharidosis VI and VII Gustavo Monteiro VIANA1; Camila de Britto Ponte DocID: 1v8Z4 - View Document
	What is HUNTER SYNDROME? Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare and progressive lysosomal storage disease inherited in an X-linked recessive DocID: 1lIxr - View Document
	MUCOPOLYSACCHARIDOSES Rare Diseases Unit of the Finnish Association of People with Physical Disabilities Support for this guide was provided by Genzyme. DocID: 1fJSQ - View Document
	May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im DocID: 1aiEg - View Document
	Microsoft Word - Apjohn Ventures Fund 2Q10 Letter Final DocID: 19Qom - View Document